1st Quarter Results

Summary by AI ^BETAClose X

AstraZeneca reported strong first-quarter 2026 results with total revenue increasing 8% to $15,288 million, driven by double-digit growth in Oncology and Rare Disease segments. Core EPS grew 5% to $2.58, and the company reaffirmed its full-year guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth. Key pipeline advancements include positive Phase III readouts for tozorakimab and efzimfotase alfa, alongside 14 regulatory approvals in major regions since the prior results announcement. The company also announced significant business development activity, including a $1.2 billion strategic collaboration with CSPC Pharmaceuticals for obesity and type 2 diabetes therapies.

Disclaimer*

Companies

AstraZeneca (AZN)

UK 100

Latest directors dealings

9 hours ago Savannah Energy
10 hours ago Buccaneer Energy PLC
10 hours ago Savannah Energy
11 hours ago Carclo
11 hours ago Schroder Japan Growth Fund

All directors dealings today

	Q1 2026	% Change
	$m	Actual	CER¹
- Product Sales	14,386	12	7
- Alliance Revenue	825	29	26
Product Revenue	15,211	13	8
Collaboration Revenue	77	4	-
Total Revenue	15,288	13	8
Reported EPS ($)	1.99	6	8
Core² EPS ($)	2.58	4	5

Medicine	Trial	Indication	Event
Imfinzi	EMERALD-3	Locoregional HCC	Primary endpoint met
Imfinzi + Orpathys	SAMETA	MET+ advanced papillary renal cell carcinoma	Primary endpoint not met
tozorakimab	OBERON	COPD	Primary endpoint met
tozorakimab	TITANIA	COPD	Primary endpoint met
tozorakimab	MIRANDA	COPD	Primary endpoint met
tozorakimab	PROSPERO	COPD	Primary endpoint not met
Breztri	ATHLOS	COPD	Primary endpoint met
efzimfotase alfa	MULBERRY	HPP (paediatric, treatment-naïve)	Primary endpoint met
efzimfotase alfa	CHESTNUT	HPP (paediatric, switch from Strensiq)	Primary endpoint met
efzimfotase alfa	HICKORY	HPP (adults, adolescents, treatment-naïve)	Primary endpoint not met
Ultomiris	I CAN	IgAN	Primary endpoint met
Ultomiris	ARTEMIS	CSA-AKI	Discontinued due to inconsistent efficacy

Medicine	Trial	Indication	Region
Calquence	AMPLIFY	1L CLL (fixed duration)	US
Enhertu	DESTINY-Gastric04	2L HER2+ gastric/GEJ cancer	JP
Enhertu	DESTINY-PanTumor02	HER2-positive solid tumours	JP
Enhertu	DESTINY-Breast11	Neoadjuvant HER2+ Stage II or III breast cancer	CN
Imfinzi	MATTERHORN	Resectable gastric/GEJ cancer	EU
Imfinzi	HIMALAYA	1L HCC	CN
Imfinzi	POSEIDON	1L NSCLC	CN
Breztri	KALOS / LOGOS	Asthma	US
Saphnelo	TULIP-SC	SLE (subcutaneous)	JP, US
Tezspire	WAYPOINT	Chronic rhinosinusitis with nasal polyps	JP, CN
Tezspire	DIRECTION	Severe asthma	CN
Koselugo	KOMET	Adult NF1-PN	CN

Medicine	Trial	Indication	Region
Calquence	AMPLIFY	1L CLL (fixed duration)	JP
Calquence	ECHO	1L MCL	CN
Enhertu	DESTINY-Breast05	High-risk HER2+ early breast cancer (post-neoadjuvant)	US, EU, JP, CN
Enhertu	DESTINY-PanTumor03	HER2-expressing solid tumours	CN
Datroway	TROPION-Breast02	1L TNBC for patients where immunotherapy is not an option	JP
baxdrostat	BaxHTN / Bax24 / BaxAsia	Treatment resistant hypertension	CN

For the quarter	Reported	Change		Core	Change
ended 31 March	$m	Act	CER	$m	Act	CER
Product Revenue	15,211	13	8	15,211	13	8	* See Tables 3, 7, 25 and 26 for further details of Product Revenue, Product Sales and Alliance Revenue
Collaboration Revenue	77	4	-	77	4	-	* See Tables 4 and 27 for further details of Collaboration Revenue
Total Revenue	15,288	13	8	15,288	13	8	* See Tables 5 and 6 for Total Revenue by Therapy Area and by region
Gross Margin (%)	82	-1pp	+1pp	83	-1pp	+1pp	* Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue
R&D expense	3,492	11	7	3,461	12	8	* Core R&D: 23% of Total Revenue + Accelerated recruitment in ongoing trials + Investments in transformative technologies such as IO bispecifics, cell therapy and antibody drug conjugates + Addition of R&D projects from business development + Positive data readouts for high value pipeline opportunities that have ungated large late-stage trials
SG&A expense	4,920	10	6	3,859	12	7	* Core SG&A: 25% of Total Revenue + Investment to support ongoing and future launches
Other operating income and expense⁴	189	67	65	189	65	63	+ Various partner milestones
Operating profit	4,246	16	17	5,352	11	12
Operating Margin (%)	28	+1pp	+2pp	35	-	+1pp
Net finance expense	320	20	16	281	30	26	+ Prior year Net finance expense benefitted from adjustments relating to settlements with tax authorities
Tax rate (%)	21	+7pp	+7pp	21	+5pp	+5pp	* Prior year benefitted from the release of tax liabilities following settlements with tax authorities * Variations in the tax rate can be expected between periods
EPS ($)	1.99	6	8	2.58	4	5

	Q1 2026		% Change
	$m	% Total	Actual	CER
Tagrisso	1,833	12	9	5
Imfinzi	1,694	11	34	30
Calquence	923	6	21	17
Lynparza	781	5	8	2
Enhertu	831	5	40	34
Zoladex	315	2	8	2
Truqap	198	1	50	47
Imjudo	77	1	(5)	(7)
Datroway	43	-	>10x	>10x
Other Oncology	102	1	(8)	(10)
Oncology PR	6,797	45	20	16
Farxiga	2,193	14	7	(2)
Crestor	355	2	12	8
Lokelma	199	1	30	26
Seloken	180	1	12	7
Brilinta	105	1	(65)	(67)
Wainua	51	-	29	28
roxadustat	43	-	(45)	(48)
Other CVRM	115	1	(16)	(20)
Cardiovascular, Renal & Metabolism PR	3,241	21	-	(7)
Symbicort	747	5	3	(1)
Fasenra	483	3	15	11
Breztri	353	2	18	13
Tezspire	303	2	40	34
Saphnelo	171	1	25	24
Pulmicort	149	1	(6)	(11)
Airsupra	37	-	31	31
Other R&I	75	-	(28)	(30)
Respiratory & Immunology PR	2,318	15	11	7
Beyfortus	116	1	3	3
FluMist	8	-	>10x	>10x
Other ID	58	-	(49)	(53)
Infectious Disease PR	182	1	(19)	(22)
Ultomiris	1,270	8	21	18
Soliris	389	3	(12)	(14)
Strensiq	517	3	47	43
Koselugo	170	1	24	15
Other Rare Disease	74	-	28	18
Rare Disease PR	2,420	16	19	15
Other Medicines PR	253	2	(7)	(9)
Product Revenue	15,211	100	13	8

Alliance Revenue included above:
Enhertu	508	3	28	23
Tezspire	154	1	18	18
Beyfortus	91	1	11	11
Datroway	42	-	>10x	>10x
Other royalty revenue	29	-	22	22
Other Alliance Revenue	1	-	3	3
Alliance Revenue	825	5	29	26

Q1 2026 $m	Total Revenue		% Change Actual CER		* Strong demand growth across indications and key regions, positioned as backbone across all stages of EGFRm NSCLC. Leading combination in 1L NSCLC (FLAURA2)
US		733	8	8	* Robust underlying demand; higher Q1 inventory destocking
Emerging Markets		536	3	(1)	* Affected by tender outcomes and phasing
Europe		387	26	12
Established RoW		177	2	1	* Seasonal variability in Japan ahead of fiscal year-end
Total		1,833	9	5

Q1 2026 $m	Total Revenue		% Change Actual CER		* Strong demand growth across all regions from existing indications and new launches
US		954	31	31	* Demand growth led by new GI and GU launches (MATTERHORN, NIAGARA)
Emerging Markets		187	32	28	* Strong growth in GI (HIMALAYA, TOPAZ), ongoing launch momentum
Europe		383	52	34	* Early momentum for new lung (ADRIATIC) and GI (MATTERHORN) launches
Established RoW		170	22	22	* Demand growth from new launches across GYN (DUO-E), GU (NIAGARA), and lung
Total		1,694	34	30

	Q1 2026	Q1 2025	% Change
	$m	$m	Actual	CER
- Product Sales	14,386	12,875	12	7
- Alliance Revenue	825	639	29	26
Product Revenue	15,211	13,514	13	8
Collaboration Revenue	77	74	4	-
Total Revenue	15,288	13,588	13	8
Cost of sales	(2,678)	(2,241)	20	4
Gross profit	12,610	11,347	11	9
Distribution expense	(141)	(135)	4	(4)
R&D expense	(3,492)	(3,159)	11	7
SG&A expense	(4,920)	(4,492)	10	6
Other operating income & expense	189	113	67	65
Operating profit	4,246	3,674	16	17
Net finance expense	(320)	(265)	20	16
Joint ventures and associates	(12)	(7)	86	67
Profit before tax	3,914	3,402	15	17
Taxation	(833)	(481)	74	71
Tax rate	21%	14%
Profit after tax	3,081	2,921	5	8
Earnings per share	$1.99	$1.88	6	8

For the three months ended 31 March	Reported	Restructuring	Intangible Asset Amortisation & Impairments	Other	Core	% Change
	$m	$m	$m	$m	$m	Actual	CER
Gross profit	12,610	5	8	1	12,624	11	9
- Gross Margin	82%				83%	-1pp	+1pp
Distribution expense	(141)	-	-	-	(141)	6	(2)
R&D expense	(3,492)	21	9	1	(3,461)	12	8
- R&D % of Total Revenue	23%				23%	-	-
SG&A expense	(4,920)	34	973	54	(3,859)	12	7
- SG&A % of Total Revenue	32%				25%	-	-
Total operating expense	(8,553)	55	982	55	(7,461)	12	7
Other operating income & expense	189	-	-	-	189	65	63
Operating profit	4,246	60	990	56	5,352	11	12
- Operating Margin	28%				35%	-	+1pp
Net finance expense	(320)	-	-	39	(281)	30	26
Taxation	(833)	(13)	(190)	(22)	(1,058)	48	50
EPS	$1.99	$0.03	$0.52	$0.04	$2.58	4	5

For the three months ended 31 March	Q1 2026 $m	Q1 2025 $m	Change $m
Reported Operating profit	4,246	3,674	572
Depreciation, amortisation and impairment	1,366	1,284	82
Movement in working capital and short-term provisions	(1,000)	(426)	(574)
Gains on disposal of intangible assets	(34)	(66)	32
Fair value movements on contingent consideration arising from business combinations	1	1	-
Non-cash and other movements	(253)	31	(284)
Interest paid	(441)	(422)	(19)
Taxation paid	(526)	(363)	(163)
Net cash inflow from operating activities	3,359	3,713	(354)
Net cash outflow from investing activities	(1,792)	(1,253)	(539)
Net cash inflow/(outflow) from financing activities	267	(2,707)	2,974
Net increase/(decrease) in cash and cash equivalents in the period	1,834	(247)	2,081

	At 31 Mar 2026 $m	At 31 Dec 2025 $m	At 31 Mar 2025 $m
Cash and cash equivalents	7,560	5,711	5,230
Other investments	115	30	165
Cash and investments	7,675	5,741	5,395
Overdrafts and short-term borrowings	(597)	(644)	(445)
Commercial paper	(2,412)	-	(948)
Lease liabilities	(1,888)	(1,803)	(1,551)
Current instalments of loans	(4,567)	(2,460)	(2,010)
Non-current instalments of loans	(24,454)	(24,715)	(26,692)
Interest-bearing loans and borrowings (Gross debt)	(33,918)	(29,622)	(31,646)
Net derivatives	299	507	184
Net debt	(25,944)	(23,374)	(26,067)

	At 31 Mar 2026 $m	At 31 Mar 2025 $m
Current assets	49	68
Non-current assets	68	-
Current liabilities	(7,302)	(3,201)
Non-current liabilities	(24,440)	(26,748)
Amounts due from subsidiaries that are not issuers or guarantors	20,443	20,922
Amounts due to subsidiaries that are not issuers or guarantors	-	-

Currency	Primary Relevance	Exchange rate vs USD (average rate in period)					Annual impact of 5% strengthening vs USD¹ ($m)
		FY 20252	YTD 20263	Change (%)	Mar 20264	Change (%)	Total Revenue	Core Operating Profit
EUR	Total Revenue	0.88	0.85	4	0.87	2	499	234
CNY	Total Revenue	7.19	6.92	4	6.90	4	329	178
JPY	Total Revenue	149.64	156.85	(5)	158.64	(6)	179	120
GBP	Operating expense	0.76	0.74	2	0.75	1	50	(180)
SEK	Operating expense	9.81	9.13	7	9.31	5	9	(71)
Other							615	339

For the three months ended 31 March	2026 $m	2025 $m
- Product Sales	14,386	12,875
- Alliance Revenue	825	639
Product Revenue	15,211	13,514
Collaboration Revenue	77	74
Total Revenue	15,288	13,588
Cost of sales	(2,678)	(2,241)
Gross profit	12,610	11,347
Distribution expense	(141)	(135)
Research and development expense	(3,492)	(3,159)
Selling, general and administrative expense	(4,920)	(4,492)
Other operating income and expense	189	113
Operating profit	4,246	3,674
Finance income	73	84
Finance expense	(393)	(349)
Share of after tax losses in associates and joint ventures	(12)	(7)
Profit before tax	3,914	3,402
Taxation	(833)	(481)
Profit for the period	3,081	2,921

Other comprehensive income
Items that will not be reclassified to profit or loss:
Remeasurement of the defined benefit pension liability	75	51
Net gains/(losses) on equity investments measured at fair value through Other comprehensive income	185	(58)
Tax expense on items that will not be reclassified to profit or loss	(56)	(17)
	204	(24)
Items that may be reclassified subsequently to profit or loss:
Foreign exchange arising on consolidation	(551)	1,152
Foreign exchange arising on designated liabilities in net investment hedges	7	53
Fair value movements on cash flow hedges	(79)	72
Fair value movements on cash flow hedges transferred to profit and loss	55	(102)
Fair value movements on derivatives designated in net investment hedges	4	(10)
Costs of hedging	(16)	(8)
Tax income/(expense) on items that may be reclassified subsequently to profit or loss	7	(30)
	(573)	1,127
Other comprehensive (expense)/income for the period, net of tax	(369)	1,103

Total comprehensive income for the period	2,712	4,024

Profit attributable to:
Owners of the Parent	3,080	2,916
Non-controlling interests	1	5
	3,081	2,921

Total comprehensive income/(expense) attributable to:
Owners of the Parent	2,713	4,017
Non-controlling interests	(1)	7
	2,712	4,024
Earnings per share
Basic earnings per $0.25 Ordinary Share	$1.99	$1.88
Diluted earnings per $0.25 Ordinary Share	$1.97	$1.87
Weighted average number of Ordinary Shares in issue (millions)	1,549	1,550
Diluted weighted average number of Ordinary Shares in issue (millions)	1,561	1,561

Q1 2026 $m	Total Revenue		% Change Actual CER		* Growth driven by HF and CKD indications, SGLT2 class growth supported by cardiorenal guidelines
US		449	17	17	* Continued market share gain in growing SGLT2 market
Emerging Markets		924	6	(2)	* Affected by generic competition and VBP implementation in China in Q1 2026
Europe		778	14	-	* Demand growth offset by generic entry in the UK in Q3 2025
Established RoW		87	(56)	(58)	* Generic T2D entry in Japan in Q4 2025. Milestone receipt in the quarter
Total		2,237	5	(3)

Q1 2026 $m	Total Revenue		% Change Actual CER		* Sustained market leader in a broadly stable ICS/LABA class, treating COPD and asthma
US		290	4	4	* Demand for brand and authorised generic partially offset by price pressures
Emerging Markets		226	(3)	(7)	* Volume growth offset by continued generic erosion ex. China
Europe		152	12	-	* Volume growth offset by continued generic erosion
Established RoW		79	4	(1)
Total		747	3	(1)

Q1 2026 $m	Total Revenue		% Change Actual CER		* Fastest growing medicine within the expanding FDC triple class (ICS/LABA/LAMA), treating COPD
US		149	1	1	* Consistent share growth offset by unfavourable gross-to-net adjustments
Emerging Markets		115	28	22	* Market share leadership within FDC triple class in China
Europe		64	55	37	* Sustained growth from market share gains
Established RoW		25	25	22
Total		353	18	13

Q1 2026 $m	Total Revenue		% Change Actual CER		* Decline driven by conversion of patients to Ultomiris across all indications, competition in gMG and PNH
US		216	(25)	(25)	* Also affected by biosimilar pressure in gMG, PNH and aHUS
Emerging Markets		113	73	67	* Benefitted from favourable order timing from tender markets
Europe		32	(42)	(49)	* Also affected by biosimilar pressure in PNH and aHUS
Established RoW		28	(19)	(21)
Total		389	(12)	(14)

	At 31 Mar 2026	At 31 Dec 2025	At 31 Mar 2025
Assets	$m	$m	$m
Non-current assets
Property, plant and equipment	13,121	12,962	10,819
Right-of-use assets	1,820	1,741	1,484
Goodwill	21,194	21,242	21,130
Intangible assets	36,908	37,846	37,550
Investments in associates and joint ventures	306	302	270
Other investments	2,359	2,223	1,630
Derivative financial instruments	382	498	210
Other receivables	1,186	1,327	926
Income tax receivable	1,533	1,391	-
Deferred tax assets	5,593	5,819	6,095
	84,402	85,351	80,114
Current assets
Inventories	6,570	6,557	5,884
Trade and other receivables	14,106	15,177	13,250
Other investments	115	30	165
Derivative financial instruments	28	90	45
Intangible assets	175	-	-
Income tax receivable	1,059	1,158	1,565
Cash and cash equivalents	7,560	5,711	5,230
	29,613	28,723	26,139
Total assets	114,015	114,074	106,253

Liabilities
Current liabilities
Interest-bearing loans and borrowings	(7,576)	(3,104)	(3,403)
Lease liabilities	(383)	(382)	(355)
Trade and other payables	(22,505)	(25,280)	(22,544)
Derivative financial instruments	(103)	(81)	(22)
Provisions	(704)	(686)	(1,149)
Income tax payable	(1,299)	(1,084)	(1,656)
	(32,570)	(30,617)	(29,129)
Non-current liabilities
Interest-bearing loans and borrowings	(24,454)	(24,715)	(26,692)
Lease liabilities	(1,505)	(1,421)	(1,196)
Derivative financial instruments	(8)	-	(49)
Deferred tax liabilities	(3,471)	(3,500)	(3,553)
Retirement benefit obligations	(953)	(1,105)	(1,279)
Provisions	(904)	(918)	(922)
Income tax payable	(611)	(700)	(264)
Other payables	(2,155)	(2,379)	(2,038)
	(34,061)	(34,738)	(35,993)
Total liabilities	(66,631)	(65,355)	(65,122)

Net assets	47,384	48,719	41,131

Equity
Share capital	388	388	388
Share premium account	35,275	35,266	35,233
Other reserves	1,998	2,041	2,054
Retained earnings	9,672	10,972	3,364
Capital and reserves attributable to equity holders of the Parent	47,333	48,667	41,039
Non-controlling interests	51	52	92
Total equity	47,384	48,719	41,131

	At 1 Jan 2026	Cash flow	Acquisitions	Non-cash and other	Exchange movements	At 31 Mar 2026
	$m	$m	$m	$m	$m	$m
Non-current instalments of loans	(24,715)	(1,990)	-	2,136	115	(24,454)
Non-current instalments of leases	(1,421)	-	-	(99)	15	(1,505)
Total long-term debt	(26,136)	(1,990)	-	2,037	130	(25,959)
Current instalments of loans	(2,460)	2	-	(2,122)	13	(4,567)
Current instalments of leases	(382)	115	-	(120)	4	(383)
Commercial paper	-	(2,412)	-	-	-	(2,412)
Collateral received from derivative counterparties	(473)	90	-	-	-	(383)
Other short-term borrowings excluding overdrafts	(158)	(12)	-	-	2	(168)
Overdrafts	(13)	(34)	-	-	1	(46)
Total current debt	(3,486)	(2,251)	-	(2,242)	20	(7,959)
Gross borrowings	(29,622)	(4,241)	-	(205)	150	(33,918)
Net derivative financial instruments	507	152	-	(360)	-	299
Net borrowings	(29,115)	(4,089)	-	(565)	150	(33,619)
Cash and cash equivalents	5,711	1,868	-	-	(19)	7,560
Other investments - current	30	85	-	-	-	115
Cash and investments	5,741	1,953	-	-	(19)	7,675
Net debt	(23,374)	(2,136)	-	(565)	131	(25,944)

For the three months	World			US		Emerging Markets			Europe			Established RoW
ended 31 March		Change			Change		Change			Change			Change
	$m	Act %	CER %	$m	Act %	$m	Act %	CER %	$m	Act %	CER %	$m	Act %	CER %
Tagrisso	1,833	9	5	733	8	536	3	(1)	387	26	12	177	2	1
Imfinzi	1,694	34	30	954	31	187	32	28	383	52	34	170	22	22
Calquence	923	21	17	599	18	70	30	22	218	28	13	36	16	13
Lynparza	781	8	2	308	(1)	174	8	(1)	239	22	8	60	4	3
Enhertu	324	63	56	-	-	216	59	54	64	48	29	44	n/m	n/m
Zoladex	304	7	2	5	(2)	241	8	3	39	17	4	19	(10)	(13)
Truqap	198	50	47	138	24	18	n/m	n/m	31	n/m	99	11	n/m	n/m
Imjudo	77	(5)	(7)	49	(9)	6	28	24	13	20	6	9	(22)	(22)
Datroway	1	n/m	n/m	-	-	1	n/m	n/m	-	-	-	-	-	-
Other Oncology	101	(8)	(11)	2	(32)	72	(4)	(8)	4	(23)	(32)	23	(13)	(12)
Oncology	6,236	19	15	2,788	16	1,521	15	10	1,378	34	18	549	13	12
Farxiga	2,193	7	(1)	449	17	924	6	(2)	778	14	-	42	(65)	(67)
Crestor	354	12	8	8	(28)	314	15	11	-	-	-	32	-	1
Brilinta	105	(65)	(67)	14	(92)	76	3	(2)	13	(77)	(79)	2	(37)	(43)
Lokelma	199	30	26	79	14	45	47	41	41	59	43	34	23	24
Seloken	180	12	7	-	-	174	12	7	5	10	10	1	(12)	(20)
roxadustat	43	(45)	(47)	-	-	43	(45)	(47)	-	-	-	-	-	-
Wainua	51	29	28	45	15	2	n/m	n/m	3	n/m	n/m	1	-	-
Other CVRM	115	(16)	(20)	(2)	n/m	75	5	1	28	(27)	(33)	14	(7)	(7)
CVRM	3,240	-	(6)	593	(14)	1,653	7	-	868	8	(5)	126	(37)	(38)
Symbicort	747	3	(1)	290	4	226	(3)	(7)	152	12	-	79	4	(1)
Fasenra	483	15	11	256	3	46	70	63	129	25	10	52	34	31
Breztri	353	18	13	149	1	115	28	22	64	55	37	25	25	22
Tezspire	149	73	58	-	-	20	n/m	n/m	95	68	50	34	46	45
Saphnelo	171	25	24	142	18	5	67	61	17	88	66	7	53	52
Pulmicort	149	(6)	(11)	2	(17)	122	(4)	(9)	17	(11)	(21)	8	(15)	(18)
Airsupra	37	31	31	33	18	4	n/m	n/m	-	-	-	-	-	-
Other R&I	61	(37)	(40)	8	(81)	27	(36)	(37)	24	81	68	2	(8)	(12)
R&I	2,150	10	6	880	2	565	7	2	498	32	17	207	19	15
Beyfortus	24	(19)	(18)	23	(18)	-	-	-	1	n/m	n/m	-	-	-
FluMist	8	n/m	n/m	-	-	-	-	-	-	-	-	8	n/m	n/m
Other ID	58	(49)	(53)	-	n/m	40	(52)	(56)	15	(42)	(49)	3	(41)	(41)
ID*	90	(37)	(41)	23	(15)	40	(52)	(55)	16	(40)	(47)	11	67	55
Ultomiris	1,270	21	18	679	12	103	98	93	298	31	16	190	14	14
Soliris	389	(12)	(14)	216	(25)	113	73	67	32	(42)	(49)	28	(19)	(21)
Strensiq	517	47	43	407	53	49	44	18	32	20	6	29	13	13
Koselugo	170	24	15	42	(21)	61	54	39	49	45	28	18	69	69
Other Rare Disease	74	28	18	28	7	21	47	21	20	32	16	5	n/m	n/m
Rare Disease	2,420	19	15	1,372	11	347	69	57	431	20	6	270	13	13
Other Medicines	250	(7)	(9)	23	22	192	(7)	(9)	15	(23)	(30)	20	(15)	(17)
Total Medicines	14,386	12	7	5,679	9	4,318	11	5	3,206	22	8	1,183	5	4

Registered office	UK Registrar and Transfer Office	Swedish Central Securities Depository	US Registrar and Transfer Agent
1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA	Computershare Investor Services PLC The Pavilions Bridgwater Road Bristol BS99 6ZZ	Euroclear Sweden AB PO Box 191 SE-101 23 Stockholm	Computershare Investor Services PO Box 43078 Providence RI, 02940-3078
UK	UK	Sweden	US
+44 (0) 20 3749 5000	0800 707 1682 (UK only)	+46 (0) 8 402 9000	+1 (888) 697 8018 (US only)
	+44 (0) 370 707 1682		+1 (781) 575 2844

1st Quarter Results

Summary by AI BETAClose X

Companies

UK 100

Latest directors dealings

Summary by AI ^BETAClose X